New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
07:09 EDTLLYEli Lilly acquires all development rights for calcitonin peptide antibody
Eli Lilly and Company announced that, based on positive Phase 2 data, it has acquired all development rights for a calcitonin gene-related peptide, or CGRP, antibody currently being studied as a potential treatment for the prevention of frequent, recurrent migraine headaches. CGRP is a sensory neuropeptide with vascular and pro-inflammatory effects, two processes that have been implicated in migraine headaches. This novel molecule was discovered by Lilly scientists and then licensed to Arteaus Therapeutics for development in the clinical proof-of-concept study. Financial terms of the deal were not disclosed.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 24, 2015
06:34 EDTLLYEli Lilly CEO states company is not for sale, Financial Times says
Subscribe for More Information
February 23, 2015
08:31 EDTLLYEli Lilly announces delay in submission of basal insulin peglispro beyond Q1
Subscribe for More Information
07:06 EDTLLYEli Lilly and Incyte announces positive results for baricitinib
Subscribe for More Information
February 19, 2015
08:04 EDTLLYEli Lilly extends Evacetrapib Phase 3 trial by six months
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use